Analysis Of Income And Expense [Abstract]

ABIVAX - Filing #5984181

Concept 2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
Analysis of income and expense [abstract]
Material income and expense [abstract]
Research and development expense
146 532 EUR
103 176 EUR
48 295 EUR
Finance income (cost)
3 258 EUR
20 364 EUR
4 096 EUR
Selling, general and administrative expense [abstract]
General and administrative expense
32 946 EUR
22 390 EUR
7 492 EUR
Revenue and other operating income
12 449 EUR
4 621 EUR
4 583 EUR
Operating expense
185 433 EUR
131 997 EUR
69 419 EUR
Sales and marketing expense
5 954 EUR
6 431 EUR
EUR
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations
187,000 EUR
112,000 EUR
EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
EUR
176 242 EUR
EUR
176 461 EUR
187,000 EUR
31,000 EUR
EUR
147 516 EUR
147 740 EUR
EUR
112,000 EUR
112,000 EUR
60 740 EUR
235,000 EUR
EUR
60 506 EUR
EUR
EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.